B16 tumors treated with these combination regimens exhibited increased frequencies of CD68+MHC-II+ M1 macrophages and mature CD11c+MHC-II+DC when compared to tumors treated only with ADU-S100, suggesting that addition of anti-PD-L1 or anti-ISG15 antibodies to STING agonist-based protocols promotes a qualitatively superior pro-inflammatory/anti-tumor TME from an innate immune cell perspective. The gene discussed is ISG15; the disease is neoplasm.